Evidence map›Paper›PMID 36826114›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study.

Christa Aubrey, Gregory R Pond, Limor Helpman, Danielle Vicus, Laurie Elit, Marie Plante, Susie Lau, Janice S Kwon, Alon D Altman, Karla Willows and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 1 country.

Christa AubreyDivision of Gynecologic Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.ORCID 0000-0002-0054-808X
Gregory R PondDepartment of Oncology, Escarpment Cancer Research Institute, McMaster University, Hamilton, ON L8V 5C2, Canada.
Limor HelpmanDivision of Gynecologic Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON L8V 5C2, Canada.
Danielle VicusDivision of Gynecologic Oncology, Sunnybrook Health Science Center, University of Toronto, Toronto, ON M4N 3M5, Canada.
Laurie ElitDivision of Gynecologic Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON L8V 5C2, Canada.ORCID 0000-0001-8966-1937
Marie PlanteDivision of Gynecologic Oncology, Centre Hospitalier Universite de Quebec, Laval University, Quebec City, QC G1R 2J6, Canada.
Susie LauDivision of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Janice S KwonDivision of Gynecologic Oncology, Vancouver General Hospital, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Alon D AltmanDivision of Gynecologic Oncology, Winnipeg Women's Hospital, University of Manitoba, Winnipeg, MB R3E 0L8, Canada.ORCID 0000-0002-6345-4910
Karla WillowsDivision of Gynecologic Oncology, Queen Elizabeth II Health Science Center, Dalhousie University, Halifax, NS B3K 4N1, Canada.
Tomer FeigenbergDivision of Gynecologic Oncology, Trillium Health Partners, Mississauga, University of Toronto, Toronto, ON L5B 1B8, Canada.
Jeanelle SabourinDivision of Gynecologic Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.ORCID 0000-0001-7855-962X
Vanessa SamouelianDivision of Gynecologic Oncology, Centre Hospitalier de l'Universite de Montreal, University of Montreal, Montreal, QC H2X 3E4, Canada.
Laurence BernardDivision of Gynecologic Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON L8V 5C2, Canada.
Norah CockburnDivision of Gynecologic Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON L8V 5C2, Canada.
Nora-Beth SaundersDivision of Gynecologic Oncology, Winnipeg Women's Hospital, University of Manitoba, Winnipeg, MB R3E 0L8, Canada.
Sabrina PiedimonteDivision of Gynecologic Oncology, Sunnybrook Health Science Center, University of Toronto, Toronto, ON M4N 3M5, Canada.
Ly-Ann Teo-FortinDivision of Gynecologic Oncology, Centre Hospitalier Universite de Quebec, Laval University, Quebec City, QC G1R 2J6, Canada.
Soyoun Rachel KimDivision of Gynecologic Oncology, Sunnybrook Health Science Center, University of Toronto, Toronto, ON M4N 3M5, Canada.
Noor SadeqDivision of Gynecologic Oncology, Queen Elizabeth II Health Science Center, Dalhousie University, Halifax, NS B3K 4N1, Canada.
Ji-Hyun JangDivision of Gynecologic Oncology, Vancouver General Hospital, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Sarah ShamiyaDepartment of Obstetrics and Gynecology, University of Alberta, Edmonton, AB T5H 3V9, Canada.
Gregg NelsonDivision of Gynecologic Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB T2N 4N2, Canada.ORCID 0000-0002-8177-1098
Juravinski Cancer Centre · CASunnybrook Health Science Centre · CAUniversity of Alberta · CACentre hospitalier de l'Université Laval · CAChildren's Hospital of Winnipeg · CADalhousie University · CAUniversity of British Columbia · CACentre Hospitalier de l’Université de Montréal · CAJewish General Hospital · CAMcMaster University · CAUniversity of Calgary · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Minimally invasive surgery for the treatment of macroscopic cervical cancer leads to worse oncologic outcomes than with open surgery. Preoperative conization may mitigate the risk of surgical approach. Our objective was to describe the oncologic outcomes in cases of cervical cancer initially treated with conization, and subsequently found to have no residual cervical cancer after hysterectomy performed via open and minimally invasive approaches. This was a retrospective cohort study of surgically treated cervical cancer at 11 Canadian institutions from 2007 to 2017. Cases initially treated with cervical conization and subsequent hysterectomy, with no residual disease on hysterectomy specimen were included. They were subdivided according to minimally invasive (laparoscopic/robotic (MIS) or laparoscopically assisted vaginal/vaginal hysterectomy (LVH)), or abdominal (AH). Recurrence free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier analysis. Chi-square and log-rank tests were used to compare between cohorts. Within the total cohort, 238/1696 (14%) had no residual disease on hysterectomy specimen (122 MIS, 103 AH, and 13 VLH). The majority of cases in the cohort were FIGO 2018 stage IB1 (43.7%) and underwent a radical hysterectomy (81.9%). There was no statistical difference between stage, histology, and radical vs simple hysterectomy between the abdominal and minimally invasive groups. There were no significant differences in RFS (5-year: MIS/LVH 97.7%, AH 95.8%,

Indexed as

Uterine Cervical NeoplasmsCanadaFemaleHumansHysterectomyNeoplasm StagingRetrospective Studiescervical cancerminimally invasive surgery

Identifiers

PMID36826114
PMCPMC9955159
OpenAlexW4319297233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.